Could Viking Therapeutics Be the Next Eli Lilly?

Viking Therapeutics' VK2735 is advancing in late-stage obesity trials, with the injectable version in phase 3 and the oral version slated to enter phase 3 in Q4. The company reported up to more than 14% mean body-weight reduction at 13 weeks in phase 2, positioning it as a potential competitor in a weight-loss market analysts size at nearly $100 billion by decade-end. While the article is optimistic about Viking's prospects, it emphasizes that Eli Lilly's 60% U.S. GLP-1 market share and scale advantages make a takeover of the category leader unlikely.

Analysis

The key market implication is not that VKTX needs to beat the incumbents on efficacy; it needs to clear the much harder commercialization hurdle of being a credible third source in a supply-constrained category. If phase 3 remains clean, even a sub-scale launch can matter because GLP-1 demand is still outpacing real-world availability, which means incremental capacity is monetizable before peak share is won. That creates a path where VKTX can be more valuable as a capacity-relief asset than as a category winner.

The second-order effect is pressure on pricing discipline across the class. A validated dual-agonist oral/injectable platform would force Lilly and Novo to defend both share and regimen convenience, likely accelerating payer negotiations and rebate intensity before the market fully matures. The most vulnerable names are not the leaders, but adjacent obesity plays and generic oral pipeline names that depend on a cleaner binary market with fewer credible alternatives.

Timing matters: the next 6-12 months are a data and financing window, not a revenue window. The stock should trade on phase 3 execution probability and manufacturing credibility, while the real earnings impact is years away; that asymmetry makes the name highly sensitive to trial noise and dilution risk. A single clinical hiccup or launch-capex warning could compress the multiple sharply, while a clean readout could re-rate the equity well before approval.

Consensus is likely underestimating how much optionality is embedded in having both oral and injectable formats, because it expands addressable patient segments rather than just competing on the same segment. The market also seems to over-anchor on Lilly’s moat as if manufacturing scale is static; in reality, obesity is one of the few pharma categories where supply chain execution and fill-finish capacity can still meaningfully reshape share over a 2-3 year horizon.

Key Decisions for Investors

• Long VKTX into phase 3 milestones only via defined-risk structures: buy 6-12 month call spreads to capture upside from a clean data run while limiting dilution and trial-failure downside.
• Pair trade: long VKTX / short NVO on a 3-6 month horizon if you expect the market to reward pipeline optionality over legacy oral GLP-1 share; thesis is VKTX has more convexity while NVO faces greater margin pressure from class pricing.
• Use LLY as the defensive hedge in a VKTX basket: if accumulating VKTX common, offset with a smaller short-dated LLY put spread to reduce beta to the broader obesity complex while keeping idiosyncratic upside.
• Avoid chasing straight common equity after large gap-ups; add only on post-volatility pullbacks, because the stock is likely to trade headline-to-headline until phase 3 confirmation reduces binary risk.
• Watch for any manufacturing-capex or partnering announcement as the real inflection point; if VKTX secures external capacity, that is more bullish than a modest efficacy beat because it directly addresses the market’s biggest skepticism.